All Stories

  1. Abstract 3869: Leveraging CpG methylation signatures for robust multi-class cancer classification across platforms

    Article • Cancer Research, May 2026, American Association for Cancer Research (AACR)

    Dr. Marco A. De Velasco

  2. Abstract 7170: AKT inhibition with capivasertib counteracts tumor microenvironment remodeling and enhances AR-targeted therapy in PTEN-deficient prostate cancer

    Article • Cancer Research, April 2026, American Association for Cancer Research (AACR)

    Dr. Marco A. De Velasco

  3. Abstract 371: Integrative analysis of capivasertib mediated AKT blockade with AR inhibition in mouse PTEN-deficient prostate cancer.

    Article • Cancer Research, April 2026, American Association for Cancer Research (AACR)

    Dr. Marco A. De Velasco

  4. A Case of Upper Tract Urothelial Carcinoma With Neuroendocrine Differentiation Successfully Treated With Enfortumab Vedotin and Pembrolizumab

    Article • IJU Case Reports, February 2026, Wiley

    Dr. Marco A. De Velasco

  5. Clonal Complexity Defines Distinct Tumor‐Intrinsic Biology and Prognosis in Diffuse Large B‐Cell Lymphoma

    Article • Cancer Medicine, February 2026, Wiley

    Dr. Marco A. De Velasco

  6. Comparison of genetic mutations in bladder cancers that arose following radiotherapy for prostate cancer with those in primary bladder cancers

    Article • Scientific Reports, July 2025, Springer Science + Business Media

    Dr. Marco A. De Velasco

  7. IP26-15 DIFFERENCES BETWEEN THE GUT MICROBIOTA OF HORMONE-SENSITIVE PROSTATE CANCER AND CASTRATIONRESISTANT PROSTATE CANCER IN JAPANESE MEN

    Article • The Journal of Urology, May 2025, Wolters Kluwer Health

    Dr. Marco A. De Velasco

  8. Exploration of genes related to the development of cancer of unknown primary

    Article • Oncology Reports, April 2025, Spandidos Publications

    Dr. Marco A. De Velasco

  9. Abstract 1686: Enhancing chemotherapy efficacy in PTEN-deficient prostate tumors with targeted AKT inhibition

    Article • Cancer Research, April 2025, American Association for Cancer Research (AACR)

    Dr. Marco A. De Velasco

  10. Abstract 1685: Evaluation of antitumor and molecular responses to abiraterone acetate plus capivasertib in mouse PTEN-deficient prostate cancer

    Article • Cancer Research, April 2025, American Association for Cancer Research (AACR)

    Dr. Marco A. De Velasco

  11. Immunohistochemical Analysis of Androgen Receptor Expression Predicts the Prognosis of Metastatic Castration‐Sensitive Prostate Cancer Patients Receiving Abiraterone Acetate

    Article • The Prostate, January 2025, Wiley

    Dr. Marco A. De Velasco

  12. Comparative analysis of gut microbiota in hormone‐sensitive and castration‐resistant prostate cancer in Japanese men

    Article • Cancer Science, December 2024, Wiley

    Dr. Marco A. De Velasco

  13. A machine learning-based method for feature reduction of methylation data for the classification of cancer tissue origin

    Article • International Journal of Clinical Oncology, September 2024, Springer Science + Business Media

    Dr. Marco A. De Velasco

  14. Exploring the relationship between ulcerative colitis, colorectal cancer, and prostate cancer

    Article • Human Cell, August 2024, Springer Science + Business Media

    Dr. Marco A. De Velasco

  15. A cross‐species analysis of fecal microbiomes in humans and mice reveals similarities and dissimilarities associated with prostate cancer risk

    Article • The Prostate, August 2024, Wiley

    Dr. Marco A. De Velasco

  16. Abstract 5343: Depletion of gut microbiota with broad spectrum antibiotics drives Pten-null prostate cancer growth in mice

    Article • Cancer Research, March 2024, American Association for Cancer Research (AACR)

    Dr. Marco A. De Velasco

  17. Abstract 2706: Identification and characterization of cancer-associated polymorphonuclear cell subsets in mice

    Article • Cancer Research, March 2024, American Association for Cancer Research (AACR)

    Dr. Marco A. De Velasco

  18. Abstract 4331: Machine learning-based classification of tissue origin of cancer using methylation profiles

    Article • Cancer Research, March 2024, American Association for Cancer Research (AACR)

    Dr. Marco A. De Velasco

  19. Abstract 5344: Myeloid populations upregulated in prostate cancer are associated with colitis induced colorectal cancer

    Article • Cancer Research, March 2024, American Association for Cancer Research (AACR)

    Dr. Marco A. De Velasco

  20. Abstract 104: Profiling peripheral blood to predict response to targeted androgen receptor axis therapy in mice

    Article • Cancer Research, March 2024, American Association for Cancer Research (AACR)

    Dr. Marco A. De Velasco

  21. Downregulated expression of PBRM1 in sarcomatoid hepatocellular carcinoma

    Article • Oncology Letters, January 2024, Spandidos Publications

    Dr. Marco A. De Velasco

  22. Moving toward improved immune checkpoint immunotherapy for advanced prostate cancer

    Article • International Journal of Urology, January 2024, Wiley

    Dr. Marco A. De Velasco

  23. Abstract 6330: Countering antidrug antibodies to programmed cell death-1 blockade in mouse Pten-null prostate cancer

    Article • Cancer Research, April 2023, American Association for Cancer Research (AACR)

    Dr. Marco A. De Velasco

  24. Abstract 640: Exploring the relationships between prostate cancer, colorectal cancer, and ulcerative colitis

    Article • Cancer Research, April 2023, American Association for Cancer Research (AACR)

    Dr. Marco A. De Velasco

  25. Abstract 1838: Immunomodulatory effects of curcumin monoglucuronide on PD1 immune checkpoint blockade in mouse Pten-null prostate cancer

    Article • Cancer Research, April 2023, American Association for Cancer Research (AACR)

    Dr. Marco A. De Velasco

  26. Abstract 3044: Integrative gut microbiome analysis of human and mouse prostate cancer

    Article • Cancer Research, April 2023, American Association for Cancer Research (AACR)

    Dr. Marco A. De Velasco

  27. Abstract 2877: Profiling of myeloid-derived suppressor cells in Pten-deficient in prostate cancer progression

    Article • Cancer Research, April 2023, American Association for Cancer Research (AACR)

    Dr. Marco A. De Velasco

  28. Abstract 5155: Targeting tumor infiltrating myeloid cells in prostate cancer

    Article • Cancer Research, April 2023, American Association for Cancer Research (AACR)

    Dr. Marco A. De Velasco

  29. The Gut-Prostate Axis: A New Perspective of Prostate Cancer Biology through the Gut Microbiome

    Article • Cancers, February 2023, MDPI AG

    Dr. Marco A. De Velasco

  30. Emerging Relationship between the Gut Microbiome and Prostate Cancer

    Article • The World Journal of Men s Health, January 2023, XMLink

    Dr. Marco A. De Velasco

  31. Performance of Idylla™ RAS-BRAF mutation test for formalin-fixed paraffin-embedded tissues of colorectal cancer

    Article • International Journal of Clinical Oncology, April 2022, Springer Science + Business Media

    Dr. Marco A. De Velasco

  32. Gut microbiome and prostate cancer

    Article • International Journal of Urology, April 2022, Wiley

    Dr. Marco A. De Velasco

  33. Connecting the Dots Between the Gut–IGF-1–Prostate Axis: A Role of IGF-1 in Prostate Carcinogenesis

    Article • Frontiers in Endocrinology, March 2022, Frontiers

    Dr. Marco A. De Velasco

  34. Patients with polyclonal hepatocellular carcinoma are at a high risk of early recurrence and have a poor recurrence-free survival period

    Article • Hepatology International, January 2022, Springer Science + Business Media

    Dr. Marco A. De Velasco

  35. Intestinal Microbiota and Gene Expression Reveal Similarity and Dissimilarity Between Immune-Mediated Colitis and Ulcerative Colitis

    Article • Frontiers in Oncology, October 2021, Frontiers

    Dr. Marco A. De Velasco

  36. Disseminated intravascular coagulation induced by pazopanib following combination therapy of nivolumab plus ipilimumab in a patient with metastatic renal cell carcinoma

    Article • Anti-Cancer Drugs, August 2021, Wolters Kluwer Health

    Dr. Marco A. De Velasco

  37. Context-Specific Efficacy of Apalutamide Therapy in Preclinical Models of Pten-Deficient Prostate Cancer

    Article • Cancers, August 2021, MDPI AG

    Dr. Marco A. De Velasco

  38. Integrative analysis of gut microbiome and host transcriptomes reveals associations between treatment outcomes and immunotherapy‐induced colitis

    Article • Molecular Oncology, July 2021, Wiley

    Hisato Kawakami, Dr. Marco A. De Velasco

  39. Transcriptome Profiling and Metagenomic Analysis Help to Elucidate Interactions in an Inflammation-Associated Cancer Mouse Model

    Article • Cancers, July 2021, MDPI AG

    Dr. Marco A. De Velasco

  40. Higher neutrophil-to-lymphocyte ratio after the first cycle of the first-line chemotherapy is associated with poor cancer specific survival of upper urinary tract carcinoma patients

    Article • Translational Andrology and Urology, July 2021, AME Publishing Company

    Dr. Marco A. De Velasco

  41. Mucosal microbiota and gene expression are associated with long-term remission after discontinuation of adalimumab in ulcerative colitis

    Article • Scientific Reports, November 2020, Springer Science + Business Media

    Yoriaki Komeda, Dr. Marco A. De Velasco

  42. Abstract 3416: Androgen deprivation following JAK1/2 and PD-L1 inhibition improves antitumor efficacy in mouse models of Pten-deficient prostate cancer

    Article • Cancer Research, August 2020, American Association for Cancer Research (AACR)

    Dr. Marco A. De Velasco

  43. Abstract 4468: Cross-species analysis and immunophenotyping using of a focused panel of immune-responsive genes

    Article • Cancer Research, August 2020, American Association for Cancer Research (AACR)

    Dr. Marco A. De Velasco

  44. Abstract 3340: Prostate cancer alters gut microbiota in mice

    Article • Cancer Research, August 2020, American Association for Cancer Research (AACR)

    Dr. Marco A. De Velasco

  45. Abstract 3341: Systemic targeted JAK1/2 therapy for mouse Pten-deficient prostate cancer model influences the diversity and composition of the gut microbiome

    Article • Cancer Research, August 2020, American Association for Cancer Research (AACR)

    Dr. Marco A. De Velasco

  46. Abstract 1071: Targeting A2aR in mouse Pten-deficient prostate cancer

    Article • Cancer Research, August 2020, American Association for Cancer Research (AACR)

    Dr. Marco A. De Velasco

  47. Abstract 5610: The multi tyrosine kinase inhibitor TAS-115 promotes innate and adaptive immune responses of androgen deprivation therapy in mouse prostate cancer

    Article • Cancer Research, August 2020, American Association for Cancer Research (AACR)

    Dr. Marco A. De Velasco

  48. Chemopreventive effects of nanoparticle curcumin in a mouse model of Pten-deficient prostate cancer

    Article • Human Cell, March 2020, Springer Science + Business Media

    Dr. Marco A. De Velasco

  49. Targeting castration-resistant prostate cancer with androgen receptor antisense oligonucleotide therapy

    Article • JCI Insight, September 2019, American Society for Clinical Investigation

    Dr. Marco A. De Velasco

  50. Abstract 4996: A real-time PCR-based approach to quantitatively assess tumor immune profiles and immune responses

    Article • Cancer Research, July 2019, American Association for Cancer Research (AACR)

    Dr. Marco A. De Velasco

  51. Abstract 3951: Apalutamide reworks the immune composition of prostate tumors

    Article • Cancer Research, July 2019, American Association for Cancer Research (AACR)

    Dr. Marco A. De Velasco

  52. Abstract 1613: Dietary isoflavone decreases prostate cancer progression and improves survival in conditional Pten/Trp53-deficient mice

    Article • Cancer Research, July 2019, American Association for Cancer Research (AACR)

    Dr. Marco A. De Velasco

  53. Abstract 5023: Immunomodulation of the multi-tyrosine kinase inhibitor TAS-115 in a mouse model of prostate cancer

    Article • Cancer Research, July 2019, American Association for Cancer Research (AACR)

    Dr. Marco A. De Velasco

  54. HOXA10 expression profiling in prostate cancer

    Article • The Prostate, January 2019, Wiley

    Dr. Marco A. De Velasco

  55. Generation of PTEN‑knockout (‑/‑) murine prostate cancer cells using the CRISPR/Cas9 system and comprehensive gene expression profiling

    Article • Oncology Reports, September 2018, Spandidos Publications

    Dr. Marco A. De Velasco

  56. Abstract 3737: Apalutamide (ARN-509) demonstrates therapeutic efficacy in genetically engineered mouse models of Pten-deficient prostate cancer

    Article • Cancer Research, July 2018, American Association for Cancer Research (AACR)

    Dr. Marco A. De Velasco

  57. Abstract 947: Influence of abiraterone therapy on anti-tumor immunity in genetically engineered mouse prostate cancer models

    Article • Cancer Research, July 2018, American Association for Cancer Research (AACR)

    Dr. Marco A. De Velasco

  58. Abstract 5169: Novel target molecules for treatment of cancer of unknown primary

    Article • Cancer Research, July 2018, American Association for Cancer Research (AACR)

    Dr. Marco A. De Velasco

  59. Abstract 2868: Preclinical evaluation of the multi tyrosine kinase inhibitor TAS-115 in genetically engineered mouse models of prostate cancer

    Article • Cancer Research, July 2018, American Association for Cancer Research (AACR)

    Dr. Marco A. De Velasco

  60. Abstract 4825: Targeting PIM and AKT kinases impairs tumor growth and improves overall survival in a murine model of advanced castration-resistant prostate cancer

    Article • Cancer Research, July 2018, American Association for Cancer Research (AACR)

    Dr. Marco A. De Velasco

  61. Abstract 1715: Treatment-dependent effects of androgen receptor signaling suppression on immune modulation in mouse Pten-deficient prostate cancer

    Article • Cancer Research, July 2018, American Association for Cancer Research (AACR)

    Dr. Marco A. De Velasco

  62. Prostate cancer immunotherapy

    Article • Current Opinion in Urology, January 2018, Wolters Kluwer Health

    Dr. Marco A. De Velasco

  63. Clonal composition of human ovarian cancer based on copy number analysis reveals a reciprocal relation with oncogenic mutation status

    Article • Cancer Letters, October 2017, Elsevier

    Dr. Marco A. De Velasco

  64. SCF-KIT signaling induces endothelin-3 synthesis and secretion: Thereby activates and regulates endothelin-B-receptor for generating temporally- and spatially-precise nitric oxide to modulate SCF- and or KIT-expressing cell functions

    Article • PLOS One, September 2017, PLOS

    Dr. Marco A. De Velasco

  65. Abstract 751: Characterization of STAT3 activation in human prostate cancer

    Article • Cancer Research, July 2017, American Association for Cancer Research (AACR)

    Dr. Marco A. De Velasco

  66. Abstract 1096: Co-targeting of AKT and Pim kinases in mouse PTEN-deficient prostate cancer

    Article • Cancer Research, July 2017, American Association for Cancer Research (AACR)

    Dr. Marco A. De Velasco

  67. Abstract 3684: Inhibition of STAT3 by antisense oligonucleotide treatment decreases the immune suppressive tumor microenvironment in syngeneic and GEM tumor models

    Article • Cancer Research, July 2017, American Association for Cancer Research (AACR)

    Dr. Marco A. De Velasco

  68. Abstract 4702: PD-L1 blockade in preclinical models of PTEN-deficient prostate cancer

    Article • Cancer Research, July 2017, American Association for Cancer Research (AACR)

    Dr. Marco A. De Velasco

  69. Abstract 1582: Therapeutic potential of combination therapy using a next generation antisense oligonucleotide targeting the androgen receptor and AKT inhibition with AZD5363 in genetically engineered mouse models of prostate cancer

    Article • Cancer Research, July 2017, American Association for Cancer Research (AACR)

    Dr. Marco A. De Velasco

  70. Efficacy of irreversible EGFR-TKIs for the uncommon secondary resistant EGFR mutations L747S, D761Y, and T854A

    Article • BMC Cancer, April 2017, Springer Science + Business Media

    Dr. Marco A. De Velasco

  71. Clinical significance of Akt2 in advanced pancreatic cancer treated with erlotinib

    Article • International Journal of Oncology, April 2017, Spandidos Publications

    Dr. Marco A. De Velasco

  72. Hypoxia-inducing factor (HIF)-1α-derived peptide capable of inducing cancer-reactive cytotoxic T lymphocytes from HLA-A24+ patients with renal cell carcinoma

    Article • International Immunopharmacology, March 2017, Elsevier

    Dr. Marco A. De Velasco

  73. FGFR gene alterations in lung squamous cell carcinoma are potential targets for the multikinase inhibitor nintedanib

    Article • Cancer Science, November 2016, Wiley

    Dr. Marco A. De Velasco

  74. MEK inhibitors against MET-amplified non-small cell lung cancer

    Article • International Journal of Oncology, October 2016, Spandidos Publications

    Dr. Marco A. De Velasco

  75. Afatinib against Esophageal or Head-and-Neck Squamous Cell Carcinoma: Significance of Activating Oncogenic HER4 Mutations in HNSCC

    Article • Molecular Cancer Therapeutics, August 2016, American Association for Cancer Research (AACR)

    Dr. Marco A. De Velasco

  76. Abstract 2014: Alternative splicing is a frequent event in mouse PTEN-deficient prostate cancer

    Article • Cancer Research, July 2016, American Association for Cancer Research (AACR)

    Dr. Marco A. De Velasco

  77. Abstract 954: Analysis of noncoding RNA expression in a mouse model of PTEN-deficient prostate cancer

    Article • Cancer Research, July 2016, American Association for Cancer Research (AACR)

    Dr. Marco A. De Velasco

  78. Abstract 4315: Effects of increased dietary fat consumption on prostate cancer progression in genetically engineered mice

    Article • Cancer Research, July 2016, American Association for Cancer Research (AACR)

    Dr. Marco A. De Velasco

  79. Abstract 3538: Effects of oral chloroquine administration on a preclinical mouse model of PTEN/p53-deficient prostate cancer

    Article • Cancer Research, July 2016, American Association for Cancer Research (AACR)

    Dr. Marco A. De Velasco

  80. Abstract 3864: The Jak1/2 inhibitor AZD1480 suppresses tumor growth and metastasis in genetically engineered mouse models of PTEN-deficient prostate cancer

    Article • Cancer Research, July 2016, American Association for Cancer Research (AACR)

    Dr. Marco A. De Velasco

  81. Sensitivities to various epidermal growth factor receptor‐tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I: What is the optimal epidermal growth factor receptor‐tyrosine ki...

    Article • Cancer Science, July 2016, Wiley

    Dr. Marco A. De Velasco

  82. Functional Analyses of Mutations in Receptor Tyrosine Kinase Genes in Non–Small Cell Lung Cancer: Double-Edged Sword of DDR2

    Article • Clinical Cancer Research, July 2016, American Association for Cancer Research (AACR)

    Dr. Marco A. De Velasco

  83. Increased FGF19 copy number is frequently detected in hepatocellular carcinoma with a complete response after sorafenib treatment

    Article • Oncotarget, June 2016, Impact Journals, LLC

    Dr. Marco A. De Velasco

  84. Significance of FGF9 gene in resistance to anti-EGFR therapies targeting colorectal cancer: A subset of colorectal cancer patients withFGF9upregulation may be resistant to anti-EGFR therapies

    Article • Molecular Carcinogenesis, February 2016, Wiley

    Dr. Marco A. De Velasco

  85. Efficacy of targeted AKT inhibition in genetically engineered mouse models of PTEN -deficient prostate cancer

    Article • Oncotarget, February 2016, Impact Journals, LLC

    Dr. Marco A. De Velasco

  86. An activating ALK gene mutation in ALK IHC-positive/FISH-negative non-small cell lung cancer

    Article • Annals of Oncology, November 2015, Elsevier

    Dr. Marco A. De Velasco

  87. Clinicopathological and genetic differences between low-grade and high-grade colorectal mucinous adenocarcinomas

    Article • Cancer, October 2015, Wiley

    Dr. Marco A. De Velasco

  88. 2169 Clinicopathological and genetic differences between low-grade and high-grade colorectal mucinous adenocarcinoma

    Article • European Journal of Cancer, September 2015, Elsevier

    Dr. Marco A. De Velasco

  89. 259 Fibroblast growth factor 9 gene amplification can induce resistance to anti-EGFR therapy in colorectal cancer

    Article • European Journal of Cancer, September 2015, Elsevier

    Dr. Marco A. De Velasco

  90. Identification of Programmed Death Ligand 1–derived Peptides Capable of Inducing Cancer-reactive Cytotoxic T Lymphocytes From HLA-A24+ Patients With Renal Cell Carcinoma

    Article • Journal of Immunotherapy, September 2015, Wolters Kluwer Health

    Dr. Marco A. De Velasco

  91. An activating ALK gene mutation in ALK IHC-positive/FISH-negative nonsmall-cell lung cancer

    Article • Annals of Oncology, August 2015, Elsevier

    Dr. Marco A. De Velasco

  92. Abstract 1845: Chloroquine demonstrates limited effectiveness in an autochthonous preclinical model of prostate cancer

    Article • Cancer Research, August 2015, American Association for Cancer Research (AACR)

    Dr. Marco A. De Velasco

  93. Abstract 1857: Effects of long-term chloroquine chemotherapy in a preclinical model of PTEN-deficient prostate cancer

    Article • Cancer Research, August 2015, American Association for Cancer Research (AACR)

    Dr. Marco A. De Velasco

  94. Abstract 1850: Evaluation of Pim-1 kinase inhibition in a preclinical model of mouse prostate cancer

    Article • Cancer Research, August 2015, American Association for Cancer Research (AACR)

    Dr. Marco A. De Velasco

  95. Abstract 5456: FGF9 gene amplification can induce resistance to anti-EGFR therapy in colorectal cancer

    Article • Cancer Research, August 2015, American Association for Cancer Research (AACR)

    Dr. Marco A. De Velasco

  96. Abstract 4212: Inhibition of mouse PTEN-deficient prostate cancer with next generation antisense oligonucleotide targeting the androgen receptor

    Article • Cancer Research, August 2015, American Association for Cancer Research (AACR)

    Dr. Marco A. De Velasco

  97. Abstract 4958: Melanoma transition is frequently accompanied by a loss of cytoglobin, a putative tumor suppressor, in melanocytes

    Article • Cancer Research, August 2015, American Association for Cancer Research (AACR)

    Dr. Marco A. De Velasco

  98. Abstract 4699: Preclinical activity of the AKT inhibitor AZD5363 in PTEN-deficient mouse models of prostate cancer

    Article • Cancer Research, August 2015, American Association for Cancer Research (AACR)

    Dr. Marco A. De Velasco

  99. Abstract 1856: Preclinical effects of dual AKT/MAPK inhibition in PTEN-deficient prostate cancer

    Article • Cancer Research, August 2015, American Association for Cancer Research (AACR)

    Dr. Marco A. De Velasco

  100. Abstract 3402: Activin signal promotes cancer progression and is involved in cachexia in a subset of pancreatic cancer

    Article • Cancer Research, August 2015, American Association for Cancer Research (AACR)

    Dr. Marco A. De Velasco

  101. EGFR and HER2 signals play a salvage role in MEK1-mutated gastric cancer after MEK inhibition

    Article • International Journal of Oncology, June 2015, Spandidos Publications

    Dr. Marco A. De Velasco

  102. Evaluation of in vivo responses of sorafenib therapy in a preclinical mouse model of PTEN-deficient of prostate cancer

    Article • Journal of Translational Medicine, May 2015, Springer Science + Business Media

    Dr. Marco A. De Velasco

  103. Extended RAS and BRAF Mutation Analysis Using Next-Generation Sequencing

    Article • PLOS One, May 2015, PLOS

    Dr. Marco A. De Velasco

  104. New polycomb group protein enhancer of zeste homolog (EZH) 2-derived peptide with the potential to induce cancer-reactive cytotoxic T lymphocytes in prostate cancer patients with HLA-A3 supertype alleles

    Article • International Immunopharmacology, May 2015, Elsevier

    Dr. Marco A. De Velasco

  105. Chronic nicotine exposure mediates resistance to EGFR-TKI in EGFR -mutated lung cancer via an EGFR signal

    Article • Lung Cancer, April 2015, Elsevier

    Dr. Marco A. De Velasco

  106. Conditional PTEN-deficient Mice as a Prostate Cancer Chemoprevention Model

    Article • Asian Pacific Journal of Cancer Prevention, March 2015, Asian Pacific Organization for Cancer Prevention

    Dr. Marco A. De Velasco

  107. Performance of a novel KRAS mutation assay for formalin-fixed paraffin embedded tissues of colorectal cancer

    Article • SpringerPlus, January 2015, Springer Science + Business Media

    Dr. Marco A. De Velasco

  108. Activin signal promotes cancer progression and is involved in cachexia in a subset of pancreatic cancer

    Article • Cancer Letters, January 2015, Elsevier

    Dr. Marco A. De Velasco

  109. Inhibition of β-Catenin Enhances the Anticancer Effect of Irreversible EGFR-TKI in EGFR-Mutated Non–small-cell Lung Cancer with a T790M Mutation

    Article • Journal of Thoracic Oncology, January 2015, Elsevier

    Dr. Marco A. De Velasco

  110. Activated MET acts as a salvage signal after treatment with alectinib, a selective ALK inhibitor, in ALK-positive non-small cell lung cancer

    Article • International Journal of Oncology, December 2014, Spandidos Publications

    Dr. Marco A. De Velasco

  111. MEK Inhibitor for Gastric Cancer with MEK1 Gene Mutations

    Article • Molecular Cancer Therapeutics, December 2014, American Association for Cancer Research (AACR)

    Dr. Marco A. De Velasco

  112. Abstract 611: Co-targeting the PI3K and androgen receptor signal pathways in castration resistant prostate cancer

    Article • Cancer Research, October 2014, American Association for Cancer Research (AACR)

    Dr. Marco A. De Velasco

  113. Abstract 613: Combining PI3K and 5alpha-reductase inhibitors improves the treatment response in a mouse model of PTEN-deficient prostate cancer

    Article • Cancer Research, October 2014, American Association for Cancer Research (AACR)

    Dr. Marco A. De Velasco

  114. Abstract 1201: Establishment and characterization of cell lines derived from a murine model of PTEN-deficient prostate cancer

    Article • Cancer Research, October 2014, American Association for Cancer Research (AACR)

    Dr. Marco A. De Velasco

  115. Abstract 4729: Expression of lumican is negatively associated with the risk of biochemical recurrence in human prostate cancer

    Article • Cancer Research, October 2014, American Association for Cancer Research (AACR)

    Dr. Marco A. De Velasco

  116. Abstract 84: Functional evaluation of synchronous inactivation of PTEN and P53 in a murine model of prostate cancer

    Article • Cancer Research, October 2014, American Association for Cancer Research (AACR)

    Dr. Marco A. De Velasco

  117. Abstract 3912: The role of autophagy in prostate tumorigenesis and its therapeutic implications

    Article • Cancer Research, October 2014, American Association for Cancer Research (AACR)

    Dr. Marco A. De Velasco

  118. Abstract 5271: Homozygous deletion of the activin A receptor, type IB gene is associated with an aggressive cancer phenotype in pancreatic cancer

    Article • Cancer Research, October 2014, American Association for Cancer Research (AACR)

    Dr. Marco A. De Velasco

  119. Synergistic antitumor effects of S-1 with eribulin in vitro and in vivo for triple-negative breast cancer cell lines

    Article • SpringerPlus, August 2014, Springer Science + Business Media

    Dr. Marco A. De Velasco

  120. Hypoxia induces resistance to ALK inhibitors in the H3122 non-small cell lung cancer cell line with an ALK rearrangement via epithelial-mesenchymal transition

    Article • International Journal of Oncology, August 2014, Spandidos Publications

    Dr. Marco A. De Velasco

  121. KIAA1199 interacts with glycogen phosphorylase kinase β-subunit (PHKB) to promote glycogen breakdown and cancer cell survival

    Article • Oncotarget, July 2014, Impact Journals, LLC

    Dr. Marco A. De Velasco

  122. Androgen deprivation induces phenotypic plasticity and promotes resistance to molecular targeted therapy in aPTEN-deficient mouse model of prostate cancer

    Article • Carcinogenesis, July 2014, Oxford University Press (OUP)

    Dr. Marco A. De Velasco

  123. Homozygous deletion of the activin A receptor, type IB gene is associated with an aggressive cancer phenotype in pancreatic cancer

    Article • Molecular Cancer, May 2014, Springer Science + Business Media

    Dr. Marco A. De Velasco

  124. Identification of erythropoietin receptor-derived peptides having the potential to induce cancer-reactive cytotoxic T lymphocytes from HLA-A24+ patients with renal cell carcinoma

    Article • International Immunopharmacology, May 2014, Elsevier

    Dr. Marco A. De Velasco

  125. Melanoma Transition Is Frequently Accompanied by a Loss of Cytoglobin Expression in Melanocytes: A Novel Expression Site of Cytoglobin

    Article • PLOS One, April 2014, PLOS

    Dr. Marco A. De Velasco

  126. Osteopontin knockdown in the kidneys of hyperoxaluric rats leads to reduction in renal calcium oxalate crystal deposition

    Article • Urolithiasis, March 2014, Springer Science + Business Media

    Dr. Marco A. De Velasco

  127. Frequent amplification of ORAOV1 gene in esophageal squamous cell cancer promotes an aggressive phenotype via proline metabolism and ROS production

    Article • Oncotarget, December 2013, Impact Journals, LLC

    Dr. Marco A. De Velasco

  128. The OCT4 pseudogene POU5F1B is amplified and promotes an aggressive phenotype in gastric cancer

    Article • Oncogene, December 2013, Springer Science + Business Media

    Dr. Marco A. De Velasco

  129. Construction of a 3D Culture Assay System for Anti-Cancer Drug Testing

    Article • Annals of Oncology, November 2013, Elsevier

    Dr. Marco A. De Velasco

  130. Overexpression of heparan sulfate 6-O-sulfotransferase-2 in colorectal cancer

    Article • Molecular and Clinical Oncology, July 2013, Spandidos Publications

    Dr. Marco A. De Velasco

  131. Abstract 4608: Autophagy is required for prostate cancer progression.

    Article • Cancer Research, April 2013, American Association for Cancer Research (AACR)

    Dr. Marco A. De Velasco

  132. Abstract 3688: Leptin contributes to prostate cancer progression.

    Article • Cancer Research, April 2013, American Association for Cancer Research (AACR)

    Dr. Marco A. De Velasco

  133. Slug increases sensitivity to tubulin‐binding agents via the downregulation of βIII and βIVa‐tubulin in lung cancer cells

    Article • Cancer Medicine, March 2013, Wiley

    Dr. Marco A. De Velasco

  134. Effects of the Rho kinase inhibitor, hydroxyfasudil, on bladder dysfunction and inflammation in rats with HCl‐induced cystitis

    Article • International Journal of Urology, February 2013, Wiley

    Dr. Marco A. De Velasco

  135. Overexpression of FOXQ1 is Important Factor in Tumorigenecity and Tumor Growth

    Article • Annals of Oncology, October 2012, Elsevier

    Dr. Marco A. De Velasco

  136. Abstract 539: A preclinical model to evaluate the risk of increased dietary fat consumption and prostate cancer progression

    Article • Cancer Research, April 2012, American Association for Cancer Research (AACR)

    Dr. Marco A. De Velasco

  137. Abstract 424: Amplification of OCT4-pseudogene POU5F1B is a poor prognostic factor in gastric cancer

    Article • Cancer Research, April 2012, American Association for Cancer Research (AACR)

    Dr. Marco A. De Velasco

  138. Abstract 2755: Enhanced anti-tumor effects using a combinatorial targeted treatment strategy in a preclinical model of prostate cancer

    Article • Cancer Research, April 2012, American Association for Cancer Research (AACR)

    Dr. Marco A. De Velasco

  139. Abstract 5178: Evaluation of lumican expression profiles in prostate cancer

    Article • Cancer Research, April 2012, American Association for Cancer Research (AACR)

    Dr. Marco A. De Velasco

  140. Abstract 3629: HOXA10 expression profiles in prostate cancer

    Article • Cancer Research, April 2012, American Association for Cancer Research (AACR)

    Dr. Marco A. De Velasco

  141. Abstract 3876: Role of Stat3 transcriptional activation in a preclinical mouse model of prostate cancer and potential as a therapeutic target

    Article • Cancer Research, April 2012, American Association for Cancer Research (AACR)

    Dr. Marco A. De Velasco

  142. Abstract 3517: Use of a novel synthetic biomaterial to induce mild whole body hyperthermia for the treatment of cancer in a preclinical model

    Article • Cancer Research, April 2012, American Association for Cancer Research (AACR)

    Dr. Marco A. De Velasco

  143. Preclinical Remodeling of Human Prostate Cancer through the PTEN/AKT Pathway

    Article • Advances in Urology, January 2012, Hindawi Publishing Corporation

    Dr. Marco A. De Velasco

  144. Aza-derivatives of resveratrol are potent macrophage migration inhibitory factor inhibitors

    Article • Investigational New Drugs, September 2011, Springer Science + Business Media

    Dr. Marco A. De Velasco

  145. Activin A inhibits vascular endothelial cell growth and suppresses tumour angiogenesis in gastric cancer

    Article • British Journal of Cancer, September 2011, Springer Science + Business Media

    Dr. Marco A. De Velasco

  146. A new molecular targeted therapeutic approach for renal cell carcinoma with a p16 functional peptide using a novel transporter system

    Article • Oncology Reports, April 2011, Spandidos Publications

    Dr. Marco A. De Velasco

  147. 1769 A PHASE I TRIAL OF VEGFR1 PEPTIDE VACCINES FOR PATIENTS WITH METASTATIC RENAL CELL CARCINOMA

    Article • The Journal of Urology, April 2011, Wolters Kluwer Health

    Dr. Marco A. De Velasco

  148. Abstract 433: Altered expression of lumican in prostate cancer is identified by microarray analysis

    Article • Cancer Research, April 2011, American Association for Cancer Research (AACR)

    Dr. Marco A. De Velasco

  149. Abstract 806: Anti-tumor effects of low temperature whole body hyperthermia on human bladder cancer cells in vivo

    Article • Cancer Research, April 2011, American Association for Cancer Research (AACR)

    Dr. Marco A. De Velasco

  150. Abstract 2167: Identification of aberrant expression of HOXA10 in prostate cancer

    Article • Cancer Research, April 2011, American Association for Cancer Research (AACR)

    Dr. Marco A. De Velasco

  151. Abstract 843: Increased consumption of dietary fat contributes to increased prostate cancer-specific mortality in a transgenic mouse model of prostate cancer

    Article • Cancer Research, April 2011, American Association for Cancer Research (AACR)

    Dr. Marco A. De Velasco

  152. Intravesical Bacillus Calmette-Guerin Therapy for Grade 3 Non-Muscle Invasive Bladder Cancer: Results of Six or Eight Successive Instillations

    Article • Current Urology, April 2011, Wolters Kluwer Health

    Dr. Marco A. De Velasco

  153. Abstract 1095: Short Poly A sequence in HGF promoter region is involved in overexpression of HGF in cancer cells

    Article • Cancer Research, April 2011, American Association for Cancer Research (AACR)

    Dr. Marco A. De Velasco

  154. Abstract 3579: Sorafenib inhibits tumor development and growth in a transgenic mouse model of prostate cancer

    Article • Cancer Research, April 2011, American Association for Cancer Research (AACR)

    Dr. Marco A. De Velasco

  155. Antitumor Activity of BIBF 1120, a Triple Angiokinase Inhibitor, and Use of VEGFR2+pTyr+ Peripheral Blood Leukocytes as a Pharmacodynamic Biomarker In Vivo

    Article • Clinical Cancer Research, March 2011, American Association for Cancer Research (AACR)

    Dr. Marco A. De Velasco

  156. Carvedilol protects tubular epithelial cells from ischemia–reperfusion injury by inhibiting oxidative stress

    Article • International Journal of Urology, October 2010, Wiley

    Dr. Marco A. De Velasco

  157. Abstract 3893: Overexpression of FOXQ1 is important factor in tumorigenicity and tumor growth

    Article • Cancer Research, April 2010, American Association for Cancer Research (AACR)

    Dr. Marco A. De Velasco

  158. Abstract 956: Targeting prostate cancer chemoprevention via the androgen receptor in a preclinical mouse model

    Article • Cancer Research, April 2010, American Association for Cancer Research (AACR)

    Dr. Marco A. De Velasco

  159. Immunological evaluation of personalized peptide vaccination monotherapy in patients with castration-resistant prostate cancer

    Article • Cancer Science, March 2010, Wiley

    Dr. Marco A. De Velasco

  160. FOXQ1 Is Overexpressed in Colorectal Cancer and Enhances Tumorigenicity and Tumor Growth

    Article • Cancer Research, February 2010, American Association for Cancer Research (AACR)

    Dr. Marco A. De Velasco

  161. Role of syndecan-1 (CD138) in cell survival of human urothelial carcinoma

    Article • Cancer Science, January 2010, Wiley

    Dr. Marco A. De Velasco

  162. Syndecan-1, a new target molecule involved in progression of androgen-independent prostate cancer

    Article • Cancer Science, July 2009, Wiley

    Dr. Marco A. De Velasco

  163. A Novel Human AlkB Homologue, ALKBH8, Contributes to Human Bladder Cancer Progression

    Article • Cancer Research, April 2009, American Association for Cancer Research (AACR)

    Dr. Marco A. De Velasco

  164. l-Arginine Decreases Fluid-Percussion Injury-Induced Neuronal Nitrotyrosine Immunoreactivity in Rats

    Article • Journal of Cerebral Blood Flow & Metabolism, July 2008, SAGE Publications

    Dr. Marco A. De Velasco

  165. Delivery of PTEN via a novel gene microcapsule sensitizes prostate cancer cells to irradiation

    Article • Molecular Cancer Therapeutics, July 2008, American Association for Cancer Research (AACR)

    Dr. Marco A. De Velasco

  166. Comparison of Akt/mTOR signaling in primary breast tumors and matched distant metastases

    Article • Cancer, April 2008, Wiley

    Dr. Marco A. De Velasco

  167. A NOVEL p16 PEPTIDE THERAPY RADIOSENSITIZES PROSTATE CANCER

    Article • The Journal of Urology, April 2008, Wolters Kluwer Health

    Dr. Marco A. De Velasco

  168. FUNCTIONAL PEPTIDE THERAPY WITH PTEN IN PROSTATE CANCER

    Article • The Journal of Urology, April 2008, Wolters Kluwer Health

    Dr. Marco A. De Velasco

  169. Tumor vaccines in renal cell carcinoma

    Article • World Journal of Urology, March 2008, Springer Science + Business Media

    Dr. Marco A. De Velasco

  170. 882: Intravesical Instillation of Liposomal Doxorubicin Nanoparticles in Mouse Superficial Bladder Cancer

    Article • The Journal of Urology, April 2007, Wolters Kluwer Health

    Dr. Marco A. De Velasco

  171. 650: The Role of PTEN in Hormone Independent Prostate Cancer Derived by Prostate Specific Deletion of PTEN

    Article • The Journal of Urology, April 2007, Wolters Kluwer Health

    Dr. Marco A. De Velasco

  172. Expression of Cellular Adhesion Proteins and Abnormal Glycoproteins in Human Aberrant Crypt Foci

    Article • Applied Immunohistochemistry & Molecular Morphology, December 2004, Wolters Kluwer Health

    Dr. Marco A. De Velasco

  173. A Missense Mutation in KIT Kinase Domain 1 Correlates with Imatinib Resistance in Gastrointestinal Stromal Tumors

    Article • Cancer Research, September 2004, American Association for Cancer Research (AACR)

    Dr. Marco A. De Velasco

  174. Intestinal expression of mutant and wild‐type progastrin significantly increases colon carcinogenesis in response to azoxymethane in transgenic mice

    Article • Cancer, February 2004, Wiley

    Dr. Marco A. De Velasco

  175. Protective effects of zinc chelation in traumatic brain injury correlate with upregulation of neuroprotective genes in rat brain

    Article • Neuroscience Letters, January 2004, Elsevier

    Dr. Marco A. De Velasco

  176. ProgastrinI-80 is a potent anti-apoptotic factor for clonic epithelial cells in vivo

    Article • Gastroenterology, April 2003, Elsevier

    Dr. Marco A. De Velasco

  177. Deletion of functional gastrin gene markedly increases colon carcinogenesis in response to azoxymethane in mice

    Article • Gastroenterology, August 2002, Elsevier

    Dr. Marco A. De Velasco

  178. Progastrin expression predisposes mice to colon carcinomas and adenomas in response to a chemical carcinogen

    Article • Gastroenterology, July 2000, Elsevier

    Dr. Marco A. De Velasco

  179. Efficacy of potential chemopreventive agents on rat colon aberrant crypt formation and progression

    Article • Carcinogenesis, June 2000, Oxford University Press (OUP)

    Dr. Marco A. De Velasco

  180. Mice overexpressing progastrin are predisposed for developing aberrant colonic crypt foci in response to AOM

    Article • AJP Gastrointestinal and Liver Physiology, March 2000, American Physiological Society

    Dr. Marco A. De Velasco

  181. Allium vegetables: their role in the prevention of cancer

    Article • Biochemical Society Transactions, August 1996, Portland Press Ltd.

    Dr. Marco A. De Velasco

  182. Inhibition of aberrant crypt growth by non‐steroidal anti‐inflammatory agents and differentiation agents in the rat colon

    Article • International Journal of Cancer, February 1995, Wiley

    Dr. Marco A. De Velasco

  183. Micronuclei, a biomarker for chemoprevention trials: Results of a randomized study in oral pre‐malignancy

    Article • International Journal of Cancer, November 1994, Wiley

    Dr. Marco A. De Velasco

  184. GFP image analysis in the mouse orthotopic bladder cancer model

    Article • Oncology Reports, January 1994, Spandidos Publications

    Dr. Marco A. De Velasco

  185. Micronuclei in bronchial biopsy specimens from heavy smokers: Characterization of an intermediate marker of lung carcinogenesis

    Article • International Journal of Cancer, August 1992, Wiley

    Dr. Marco A. De Velasco